Immune checkpoint blockade (ICB) has transformed cancer therapy by unleashing CD8+ T-cell activity through targeting the suppression of CTLA-4 and PD-1/PD-L1 signaling pathways [32]. The gene discussed is CD8A; the disease is cancer.